Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada

NCT: NCT07249489 · RECRUITING

NCT IDNCT07249489
StatusRECRUITING
Start Date2026-04
Completion2027-08

Brief Summary

The goal of this First in Human study is to learn if the Nanochon Chondrograft Implant is a safe primary surgical treatment for participants with cartilage lesions in the knee. This study will include males and females between the ages of 22 and 60.

Frequently Asked Questions

What is Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada?

Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada is a clinical trial registered under NCT07249489. Current status: RECRUITING.

What is the status of NCT07249489?

The current status of NCT07249489 (Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada) is: RECRUITING.

When did Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada start?

Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada started on 2026-04.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑